• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Primary Systemic Amyloidosis - Pipeline Review, H2 2011 - Product Image

Primary Systemic Amyloidosis - Pipeline Review, H2 2011

  • ID: 1881657
  • August 2011
  • 61 pages
  • Global Markets Direct

Primary Systemic Amyloidosis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Primary Systemic Amyloidosis - Pipeline Review, H2 2011', provides an overview of the Primary Systemic Amyloidosis therapeutic pipeline. This report provides information on the therapeutic development for Primary Systemic Amyloidosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Primary Systemic Amyloidosis. 'Primary Systemic Amyloidosis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Primary Systemic Amyloidosis.
- A review of the Primary Systemic READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Primary Systemic Amyloidosis Overview
Therapeutics Development
An Overview of Pipeline Products for Primary Systemic Amyloidosis
Primary Systemic Amyloidosis Therapeutics under Development by Companies
Primary Systemic Amyloidosis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Primary Systemic Amyloidosis Therapeutics - Products under Development by Companies
Primary Systemic Amyloidosis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Primary Systemic Amyloidosis Therapeutics Development
Takeda Pharmaceutical Company Limited
Immune System Therapeutics Ltd.
Primary Systemic Amyloidosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
MLN9708 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDX-1097 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Revlimid + Dexamethasone + Endoxan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iododoxorubicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Velcade + Dexamethasone + Melphalan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Revlimid + Cyclophosphamide + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bortezomib + Cyclophosphamide + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Dexamethasone + Melphalan + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone + Melphalan + Thalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Revlimid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Melphalan + Autologous Stem Cell Transplantation + Bortezomib + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Melphalan + Cyclophosphamide + Dexamethasone + Thalidomide + Peripheral Blood Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant interferon alfa + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim + melphalan + peripheral blood stem cell transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Dexamethasone + Melphalan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Dexamethasone + Melphalan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lenalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim + recombinant interferon alfa + sargramostim + busulfan + cyclophosphamide + melphalan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lenalidomide + Cyclophosphamide + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Melphalan + Autologous Peripheral Blood Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Primary Systemic Amyloidosis Therapeutics - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Primary Systemic Amyloidosis, H2 2011
Products under Development for Primary Systemic Amyloidosis – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Takeda Pharmaceutical Company Limited, 2011
Immune System Therapeutics Ltd., 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Discontinued Products

List of Figures
Number of Products under Development for Primary Systemic Amyloidosis, H2 2011
Products under Development for Primary Systemic Amyloidosis – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos